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On Tuesday 4th August 2020, at 6:09 p.m. local time, a large 
explosion occurred at a warehouse in the Port of Beirut, 
Lebanon, which resulted not only in the destruction of 
buildings and infrastructure in a large section of Beirut, but 
also devastated the lives of many people who were just going 
about their daily lives, leaving some 200 deaths, 6,000 
injured, 300,000 people homeless and an unknown number 
unaccounted for in its wake. Reconstruction cost of the 
various buildings and infrastructure is currently estimated at 
some $15 billion, whereas the rebuilding of the lives of many 
people in Beirut and beyond will take much more than just 
money. Lebanon cannot do this on its own, as it is highly in 
debt and its finances are nearly depleted – the country itself is 
on the brink of collapse. Assistance from the international 
community and financial institutions is very much needed, in 
order to aid this country in its endeavors to pick up the 
rubble, dust down the pieces and start rebuilding the various 
buildings and infrastructure, as well as the lives and 
livelihoods of its people – so that there may be hope for both 
Lebanon and its people! 
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Hazardous drugs are associated with causing acute and chronic side effects to 
healthcare workers that experience occupational exposures.  Antineoplastic 
drugs are known to cause headaches, nausea, vomiting, hair loss, mutagenic 
activity, spontaneous abortions, infertility, and congenital malformations.  
Currently, there are no acceptable thresholds for exposures to this type of 
hazardous drugs. The use of as low as reasonably acceptable (ALARA) is used 
for exposures to these types of drugs. Occupational exposure risk should be 
evaluated within facilities where they are used. Performing hazardous drug 
wipe sampling in areas that are high risk for contamination can provide 
information to facilities on how to protect their employees. 
 
 
Introduction and Background 
ntineoplastic drugs are a workplace hazard. These drugs are known to be toxic to cells that are 
non-cancerous (Vyas, Yiannakis, Turner and Sewell, 2013).  These types of drugs are 
associated with adverse side effects for employees with both acute and chronic exposures. 
Some of the earliest reports of these drugs posing occupational risks was in 1979 (Soteriades et al., 
2020). The levels were quantifiable in the urine of nurses handling these mutagenic drugs. Previously, 
the worker exposures were higher levels (e.g., mg/mL) and currently the exposures are much lower. 
Most exposures recently are nanograms per milliliter (ng/mL) (Soteriades et al., 2020).  Since the 
1940‟s, the toxicity of cancer treatments has been known to cause side-effects to both patients and to 
the healthcare workers handling these drugs while performing their daily duties (Soteriades et al., 
2020). Because healthcare workers handle these toxic drugs, the occupational risk should be evaluated.  
The symptoms associated with occupational exposure to Antineoplastic drugs include headaches, 
nausea, vomiting, hair loss, hypersensitivity, mutagenic activity, spontaneous abortions, infertility, and 
congenital malformations (Vyas, Yiannakis, Turner and Sewell, 2013). These symptoms have been 
reported in healthcare workers that are being exposed to these cytotoxic drugs at much lower doses 
than patients (Dugheri et al, 2018). The drugs are also known to cause irritation and/or damage to the 
skin, eyes, and mucous membranes. In another study, it was been shown that the compounds were 
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mutagenic to mammalian cells in cell cultures (Harrison, Peters, and Bing, 2006). Antineoplastics have 
no therapeutic relevance to individuals that do not require these types of drug therapies. 
By 2020, it was expected that there will be a rise in yearly cancer diagnoses to 16 million, globally 
(Dugheri et al., 2018). The market for cancer treatment drugs is expected to generate approximately US 
$161.3B by the end of 2021. Treatments included in the estimate are chemotherapy, hormone therapy, 
immunotherapy, and targeted therapy, with chemotherapy projected to be 50% of the revenue. 
Antineoplastic drugs are classified as hazardous chemicals by National Institute for Occupational 
Safety and Health (NIOSH) (Dugheri et al., 2018). 
NIOSH published the Preventing Occupational Exposures to Antineoplastic and Other Hazardous 
Drugs in Health Care Settings Alert in 2004. The list was recently updated in May 2020 to include 
newly approved drugs by the Food and Drug Administration (NIOSH, 2020). Of the drugs on this list 
from NIOSH, roughly half of them are antineoplastics. The purpose of this alert was to bring awareness 
to employees the risk involved with the handling of these drugs and outline protective measures they 
could implement for their facility (Fuller, Bain, Sperrazza, and Mazzuckelli, 2007). 
Currently, there is no safe occupational threshold, such as a Permissible Exposure Limit (PEL), for 
hazardous drugs, however, there have been proposals for possible threshold limits for single drugs only 
(NIOSH, 2020). Healthcare facilities are trying to minimize the occupational exposure by utilizing the 
NIOSH hierarchy of controls, by implementing engineering controls, administrative controls and 
personal protective equipment, as well as environmental monitoring (i.e. wipe sampling) and biological 
monitoring (laboratory testing) as a method to identify problems and create more worker awareness 
(Dugheri et al., 2018). 
The occupational exposure to hazardous drugs by healthcare workers is proposed to happen most 
commonly by dermal contact. It is not likely that healthcare workers are exposed via inhalation of the 
hazardous drugs.  Hazardous drugs that have a low molecular weight (< 500 Daltons) are of concern 
because these drugs are easily absorbed through the skin, whereas some of the current hazardous drugs 
have a molecular weight of >40,000 Daltons (Conner and Smith, 2016; Connor, Zock and Snow, 
2016).  
The larger molecular weight limits the dermal uptake from contaminated surfaces. However, nurses 
have a higher risk of exposure and possible dermal uptake of these higher molecular weight drugs due 
to constant hand-washing practices, which damages their skin and causes cracks that these drugs can 
penetrate through (Conner and Smith, 2016; Connor, Zock and Snow, 2016). 
Wipe sampling is one of the most common practices for hazardous drug contamination assessment 
(Conner and Smith, 2016; Connor, Zock and Snow, 2016). Environmental monitoring has shown that 
hazardous drugs can be found in the air and on work surfaces in sterile compounding rooms, 
manufacturing and packaging areas for the compounded sterile products and clinical administration 
areas (Harrison, Peters, and Bing, 2006). Performing hazardous drug wipe sampling in areas at risk for 
exposure can provide information for environmental monitoring on cleaning processes and handling of 
hazardous materials.  
Environmental wipe sampling has been used for the last 20 years in healthcare facilities to evaluate 
contamination within the workplace. Conner, Zock and Snow (2016) stated that other reasons for 
surface sampling is as follows: hazard identification and evaluation, exposure assessment, facility 
characterization, housekeeping, selection of engineering controls, evaluation of engineering and 
administrative/work practice controls, evaluation of exposure pathways, selection of personal 
protective equipment, compliance with regulations and standards, source identification, education and 
training, and investigation of complaints. The samples that were collected in the facilities of were not 
 
 







used for worker exposure but to look at the environmental contamination as a possibility for worker 
exposure (Conner and Smith, 2016; Connor, Zock and Snow, 2016).  
Recommended Wipe Sampling Methods 
Wipe sampling was originally developed to evaluate other agents such as lead, asbestos, 
methamphetamine, and antibiotics (Connor and Smith, 2016; Connor, Zock and Snow, 2016). This 
methodology was evaluated and applied to hazardous drugs. However, not all hazardous drugs can be 
analyzed because not all drugs have methods designed to analyze them in a laboratory. Additional 
methods can be developed for other drugs that do not currently have a testing method determined, as 
long as there are antibodies available for the drug (Conner and Smith, 2016; Connor, Zock and Snow, 
2016). 
When performing hazardous wipe sampling, there is a need to have a strategy in mind for which factors 
are to be assessed and what variables may be present in the sampling evaluation. Some factors to 
consider are the types of hazardous drugs that are being used and quantities stored and used within the 
facility. Once a sampling plan has been completed, a certified laboratory and/or industrial hygiene 
professional that conducts this type of sampling should be identified. Currently, there are no standards 
for sampling and analysis for these drugs, therefore it is essential to identify a laboratory that is 
experienced with hazardous drug wipe sampling analysis (Power, Sessink, Gesy, and Charbonneau, 
2014). The laboratory should have a validation process for the drugs their facility evaluates. These 
validation methods should include how samples are stored for stability, medium desorption efficiency, 
limits of detection and quantitation, calibration curves and quality control methods. Their method 
should give greater than 90% extraction efficiency, which is preferred, however greater than 75% 
extraction is acceptable (Conner & Smith, 2016). 
When hazardous drug wipe sampling is performed, the sample size should be no less than 100 cm
2
, 
however if a smaller sample size is used, more samples must be taken which can increase the cost of 
this testing since the cost is per wipe rather than per drug being tested for. A more acceptable size 
would be 400 cm
2
, which would give a larger sampling area and reduce the cost by not needing as 
many samples for one location. A sampling plan should be devised so that the facility knows exactly 
what locations were sampled and make note of what type of activity takes place in those locations (i.e., 
surface of the biological safety cabinet – admixing of hazardous drugs). Common locations for 
hazardous drug wipe sampling would be the geometric center of the engineering controls (biological 
safety cabinet or compounding aseptic containment isolator), where the direct compounding area is 
located. The floors directly below the engineering controls, pass-throughs from the hazardous drug 
storage into the negative pressure hazardous drug ISO Class 7 buffer areas and the pass through from 
the hazardous buffer areas to the general pharmacy, equipment, counters, storage containers, door 
handles, high touch areas, and computer keyboards (Conner and Smith, 2016; Connor, Zock and Snow, 
2016). 
Once the sampling has been completed, samples are sent overnight to a laboratory where the samples 
are processed and analyzed. Typical methods used for specimen recovery and analysis are gas 
chromatography, liquid chromatography, high-performance liquid chromatography, ultra-high-
performance liquid chromatography along with mass spectrometry, tandem mass spectrometry or 
inductively coupled plasma mass spectrometry. These methods determine the concentration of 
hazardous drugs present on the wipe samples that have been collected within the healthcare facility 











Summary and Conclusions 
Currently, no standards or regulations exist for an acceptable level of exposure to hazardous drug, and 
nothing is known about the synergistic effects multiple drugs could elicit in human systems. The only 
allowable standard for exposure is as low as reasonably achievable (ALARA). A common approach is 
put in place workplace controls, as well as implementation of personnel training on the handling of 
hazardous drugs, cleaning, deactivation and decontamination of work surfaces and surveys given to 
healthcare staff involved with the processes of admixture and administration of these therapies could 
work to lower potential contamination and the exposure of employees to these toxic drugs in the 
workplace (Soteriades, et al., 2020). Despite the usual healthcare protocols, workers may not be fully 
protected in their facilities. The overwhelming evidence is that an occupational risk persists for those 
handing antineoplastic drugs. The highest risk groups include pharmacists and their team that 
compounds antineoplastic drugs and the nursing staff that administers these drugs to patients (Vyas, 
Yiannakis, Turner and Sewell, 2013). Surface sampling should be used as part of an environmental 
monitoring program. In doing so, results will inform staff the larger picture of possible contamination 
and exposures on within the facility (Conner and Smith, 2016; Connor, Zock and Snow, 2016). 
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